{"entity":{"id":"idea-fund-shared-personalised-therapy-gmp","kind":"idea","name":"Shared modular GMP facilities for academic personalised vaccines and cell products","aka":[],"tldr":"Personalised cancer vaccines and cell therapies need a manufacturing run for each patient, and universities cannot afford their own plants. Regional closed, automated, modular GMP facilities offering slots to academic trials at cost, with common release testing and a shared quality system, modelled on the UK Cell and Gene Therapy Catapult centre, would let academic groups run these trials.","summary":"Regional facilities with closed, automated, modular manufacturing (mRNA and peptide neoantigen vaccines, autologous CAR-T and TIL, dendritic cell products) offering slots to academic trials at cost, with common release testing, digital batch records and a shared quality management system accepted by regulators. Modelled on the UK's Cell and Gene Therapy Catapult manufacturing centre and CIRM's Alpha Clinics, but explicitly for oncology personalised therapies where academic groups hold the biology but cannot manufacture. Coupled with the hospital-exemption registry and public CAR-T network, this is the manufacturing layer of an academic personalised-therapy system.","asOf":"2026-09-08","links":[{"label":"Cell and Gene Therapy Catapult","url":"https://ct.catapult.org.uk/"}],"tags":[],"related":["idea-fund-translational-institutes-gmp","idea-fund-public-car-t-manufacturing","idea-fund-academic-adc-bispecific-platform"],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine","car-t","til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Shared facilities cut the manufacturing cost per patient for academic personalised products by at least half and enable at least ten academic personalised-therapy trials per facility per year, compared with one or two in most academic centres today.","rationale":"The Cell and Gene Therapy Catapult has supported dozens of companies and academic groups with shared GMP; automated closed systems reduce staff and cleanroom costs that dominate academic manufacturing. Academic neoantigen vaccine trials have been limited by manufacturing slots, not by scientific readiness.","test":"Fund one facility for three years and track trials served, cost per product and batch success rate against academic in-house manufacturing benchmarks.","maturity":"early-clinical","actor":"engineering","cost":"large","horizonYears":4},"route":"/ideas/idea-fund-shared-personalised-therapy-gmp/","neighbours":{"idea":[{"id":"idea-fund-academic-adc-bispecific-platform","kind":"idea","name":"An open engineering platform for academic ADCs and bispecifics","route":"/ideas/idea-fund-academic-adc-bispecific-platform/"},{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/"},{"id":"idea-fund-translational-institutes-gmp","kind":"idea","name":"Regional translational institutes with academic GMP suites and IND teams","route":"/ideas/idea-fund-translational-institutes-gmp/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}]}}